CARB-X funds drug developers (therapeutics, preventatives, diagnostics) for Gram-negative bacteria and neonatal sepsis, not computational prediction platforms. This venture's ESM-2-based drug resistance prediction model is tangentially relevant to AMR drug discovery but does not match CARB-X's four explicit themes (direct-acting therapeutics, novel chemistry scaffolds, neonatal sepsis prevention, neonatal sepsis diagnostics). Better suited after productizing into a diagnostic or drug candidate.